Treatment AI Acquires Rocket Doctor to Enhance Digital Health

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

AstraZeneca, a global pharmaceutical company focused on developing life changing medicines, recently announced a C$820 Million (US$570M) investment in Canada, to expand the company’s research and development (R&D) facilities in Mississauga and relocate the company’s Canadian headquarters to a larger, state-of-the-art office. The investment will create over 700 new, good-paying jobs across Ontario’s life sciences sector and further establish the province as a global biomanufacturing and life sciences hub, leading in the development, commercialization and early adoption of innovative health products and services.

Rocket Doctor is an alumnus of our BDSP™ and CAAP® programs, and presented at the OBIO® Investment Summit.

Arsheen Kaur
Next

OBIO® secures funding from Government of Canada to expand Canada's manufacturing capabilities and bring innovations to market